Bio News
The U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s antibody therapy IMAAVY to treat warm autoimmune hemolytic anemia. IMAAVY is the first therapy to target pathogenic immunoglobulin G (IgG) autoantibodies that destroy red blood cells. Johnson & Johnson estimates IMAAVY’s peak sales potential at more than $5 billion.
BIOBOOK TEAM
biobookmedia@biobook.co.krRoche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
